Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.65 |
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.65 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | PAK4 | O96013 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | PRKCG | P05129 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | CSF1R | P07333 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955854 | 0.93 | LRRK2 (0.65) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14955390 | 0.87 | LRRK2 (0.65) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL16743258 | 0.86 | SYK (0.71) | SYKKCNH2 | |
| SCHEMBL14956381 | 0.85 | LRRK2 (0.66) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14956500 | 0.84 | LRRK2 (0.68) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14955619 | 0.84 | LRRK2 (0.67) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14955736 | 0.84 | LRRK2 (0.67) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14955677 | 0.82 | LRRK2 (0.70) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14955764 | 0.82 | LRRK2 (0.67) | LRRK2JAK2CHEK2CDC7PLK4 | |
| SCHEMBL14956519 | 0.81 | LRRK2 (0.71) | LRRK2JAK2CHEK2CDC7PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | SYK, ZAP70, LCK | LRRK2 800/4885JAK2 29/4885CHEK2 197/4885 |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | SYK, ZAP70, LCK | LRRK2 800/4885JAK2 29/4885CHEK2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.